Becton, Dickinson and Company (NYSE:BDX) Releases Quarterly Earnings Results, Beats Expectations By $0.43 EPS

Becton, Dickinson and Company (NYSE:BDX) posted its quarterly earnings data on Wednesday. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.43, Zacks reports. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. Becton, Dickinson and Company updated its FY 2025 guidance to 14.300-14.600 EPS.

Becton, Dickinson and Company Stock Up 1.1 %

NYSE BDX traded up $2.65 during trading hours on Wednesday, hitting $245.07. 2,061,265 shares of the company were exchanged, compared to its average volume of 2,046,401. The company has a 50 day moving average of $231.33 and a two-hundred day moving average of $234.02. The firm has a market cap of $71.07 billion, a price-to-earnings ratio of 41.26, a PEG ratio of 1.80 and a beta of 0.40. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $251.99. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 annualized dividend and a yield of 1.70%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 70.03%.

Becton, Dickinson and Company announced that its Board of Directors has authorized a stock buyback program on Tuesday, January 28th that authorizes the company to buyback 10,000,000 outstanding shares. This buyback authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Roland Goette sold 638 shares of the company’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $219.03, for a total transaction of $139,741.14. Following the completion of the transaction, the executive vice president now directly owns 14,217 shares of the company’s stock, valued at approximately $3,113,949.51. This represents a 4.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP David Shan sold 500 shares of the company’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total value of $120,000.00. Following the transaction, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. This represents a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 9,844 shares of company stock valued at $2,210,716. 0.36% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms recently issued reports on BDX. Piper Sandler boosted their price objective on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. StockNews.com downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $283.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.